Evaluation: how should a new treatment be evaluated?

  • J. G. McVie
Part of the Cancer Biology and Medicine book series (CABM, volume 3)

Abstract

The testing of new therapies in patients is a major challenge. The clinical trial has to be conducted to the highest ethical standards, yet it has to be designed to give the maximum chance of detecting a therapeutic effect whilst protecting patients from unnecessary exposure to an ineffective drug or unacceptable toxicity. This chapter will consider conventional cytotoxic drugs and some new molecules emerging from the laboratory which present new problems for clinical assessment.

Keywords

Epidermal Growth Factor Receptor Soft Tissue Sarcoma Capillary Leak Syndrome Familial Polyposis Coli Intermediate Marker 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rozencweig, M., Staquet, M., Pinedo, H. M., et al.(1985). EORTC Guidelines for Phase I Trials with Single Agents in Adults. Eur. J. Cancer Clin. Oncol., 21, 1005 – 1007CrossRefGoogle Scholar
  2. 2.
    EORTC Pharmacokinetics and Metabolism Group (1987). Pharmacokinetically-guided dose escalation in phase Iclinical trials. Eur. J. Cancer Clin. Oncol., 23, 1083 – 1087CrossRefGoogle Scholar
  3. 3.
    Wolff, S. N., Johnson, D. H., Hande, K. R., et al.(1983). High dose etoposide as single-agent chemotherapy for small cell carcinoma of the lung. Cancer Treat. Rep., 67, 957 – 958PubMedGoogle Scholar
  4. 4.
    Rozencweig, M., Ten Bokkel Huinink, W., Cavalli, F., et al. (1984). Randomized phase II trial of carminomycin versus 4’-epiodoxorubicin in advanced breast cancer (Early Clinical Trials Group of the European Organization for Research on Treatment of Cancer). J. Clin. Oncol. 2, 275–281Google Scholar
  5. 5.
    Lind, M. J., Margison, J. M., Cerny, T., et al.(1989). Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res., 49, 753 – 757PubMedGoogle Scholar
  6. 6.
    Bramwell, V. H. C., Mouridsen, H. T., Santoro, A., et al.(1986). Cyclophosphamide versus ifosfamide: Preliminary report of a randomized phase II trial in adult soft tissue sarcomas. Cancer Chemother. Pharmacol., 18(Suppl. 2), S13 – S16PubMedCrossRefGoogle Scholar
  7. 7.
    Henderson, I. C., Allegra, J. C., Woodcock, T., et al.(1989). Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J. Clin. Oncol., 17(5), 560 – 571Google Scholar
  8. 8.
    Van Dam F. S. A. M., Linnsen, A. C. G., Couzijn, A. L. (1988). Evaluating quality of life: Behavioural measures in clinical cancer trials. In Staquet, M., Sylvester, R., Buyse, M. (eds.) The Practice of Clinical Trials. Oxford University PressGoogle Scholar
  9. 9.
    Slevin, M. L., Clark, P. I., Joel, S. P., et al.(1989). A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J. Clin. Oncol., 7(9), 1333 – 40PubMedGoogle Scholar
  10. 10.
    Joint Committee: Cancer Research Campaign Headquarters, 2 Carlton House Terrace, London SW1, UK (1989). Operation manual for control of selection, production, preclinical toxicology and phase I trials of endocrine agents for patients with cancer. Br. J. Cancer, 60, 265–269Google Scholar
  11. 11.
    Merigan, T. C. (1988). Human interferon as a therapeutic agent. N. Engl, J. Med., 318, 1458 – 1460CrossRefGoogle Scholar
  12. 12.
    Mattson, K., Niiranen, A., Holsti, L., et al.(1989). Low dose natural ainterferon as maintenance therapy for small cell lung cancer (SCLC). A phase III study. Proc. ASCO, 8, 227Google Scholar
  13. 13.
    Bajorin, D. F., Sell, K. W., Richards, J. M., et al.(1990). A randomized trial of interleukin-2 plus lymphokine activated killer cells versus interleukin-2 alone in renal cell carcinoma. Am. Assoc. Cancer Res. Proc., 31, 186Google Scholar
  14. 14.
    Rankin, E. M., Hekman, A., Vyth Dreese, F. A., et al.(1983). Monoclonal antibodies against B-cell non-Hodgkin lymphomas (NHL). Br. J. Cancer, 48, 147 – 148Google Scholar
  15. 15.
    Kartner, N., Riordan, J. R. and Ling, V. (1983). Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science, 221, 1285 – 1287PubMedCrossRefGoogle Scholar
  16. 16.
    Degos, C., Chomienne, P., Ballerini, M. E., et al.(1990). All-trans retinoic acid: A novel differentiation therapy for acute promyelocytic leukemia. Am. Soc. Clin. Oncol. Prog. Proc., 9, 207Google Scholar
  17. 17.
    Vogelstein, B., Eric, R. F., Stanley, R., et al.(1989). Genetic alterations during colorectal tumorigenesis. Am. Assoc. Cancer Res. Proc., 30, 634 – 635Google Scholar
  18. 18.
    Waun, K., Scott, M. L., Loretta, M. I., et al.(1990). Prevention of second primary tumours with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 323, 795 – 800CrossRefGoogle Scholar
  19. 19.
    Zacharski, L. R., Henderson, W. G., Rickles, F. R., et al.(1981). Effect of warfarin on survival in small cell carcinoma of the lung. J. Am. Med. Assoc., 245, 831CrossRefGoogle Scholar
  20. 20.
    Glover, D., Glick, J. H., Weiler, C., et al.(1986). WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial. J. Clin. Oncol. 41, 584 – 588Google Scholar

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • J. G. McVie

There are no affiliations available

Personalised recommendations